Intellectual Property

Size: px
Start display at page:

Download "Intellectual Property"

Transcription

1 Intellectual Property Johnson & Johnson believes that the protection of intellectual property (IP) is essential to rewarding innovation and promoting medical advances. We are committed: to raising awareness of innovation in human health care and the importance of IP protection in driving that innovation; to providing economic incentive and safeguard mechanisms to foster healthcare solutions; and to promoting local economic growth. As part of our commitment to compassionate health care, Johnson & Johnson believes in helping the world s poorest countries face local public health crises. We are committed to extending lifesaving medical technologies and addressing unmet medical needs in developing countries around the world. We believe that the best way to address these needs is for companies to work with local governments to develop approaches that benefit all involved parties, while continuing to uphold the value of IP in all parts of the world. Johnson & Johnson recognizes the importance of international efforts that seek to improve and harmonize IP protection throughout the world. We continue to work with international organizations, national governments and regulators on topics involving international trade agreements, national laws and enforcement efforts to provide for the integrity of effective and strong IP protection systems globally. To ensure a sustainable system that balances the societal goals of both the innovator and the public, Johnson & Johnson works together with other key stakeholders on many IP topics, including those described in some detail below. These topics are relevant to all of our businesses, although in some instances they are particularly applicable to one portion of our business, such as Pharmaceuticals or Medical Devices. Patents Johnson & Johnson believes in the merits of a strong and effective patent system that supports, protects and stimulates innovation, economic growth, the transfer of technologies and the introduction of high-tech products. The effective patenting of our technologies, including our pharmaceuticals, provides Johnson & Johnson with an 1

2 incentive to invest in those technologies, and forms the foundation for maintaining a well-resourced and motivated workforce. The patent system in turn benefits society by requiring patent applicants to disclose their inventions to the world, and by motivating people and industry to compete to develop technologies, which generates sustained product improvement over time. Incremental Pharmaceutical Innovation Johnson & Johnson believes incremental pharmaceutical innovation plays an important role in improving the safety and effectiveness of pharmaceutical therapies. Incremental pharmaceutical innovation may include the discovery of new forms and uses of existing chemical compounds or substances that lead to the development of safer, more efficacious, and more useful treatments, better-suited to particular patient profiles or needs. For example, the development of a sustained-release dosage form of a known drug may result in an increase in patient adherence, which can deliver a profound patient benefit. Adequate incentives should be provided by patent systems to support and encourage the development of incremental pharmaceutical innovations, particularly when there is demonstrated improvement in the safety or effectiveness of the therapies. Johnson & Johnson does not endorse the practice of evergreening, which we view as distinct from incremental pharmaceutical innovation. Incremental Pharmaceutical Innovation Johnson & Johnson believes incremental pharmaceutical innovation plays an important role in improving the safety and effectiveness of pharmaceutical therapies. Incremental pharmaceutical innovation may include the discovery of new forms and uses of existing chemical compounds or substances that lead to the development of safer, more efficacious, and more useful treatments, better-suited to particular patient profiles or needs. For example, the development of a sustained-release dosage form of a known drug may result in an increase in patient adherence, which can deliver a profound patient benefit. Adequate incentives should be provided by patent systems to support and encourage the development of incremental pharmaceutical innovations, particularly when there is demonstrated improvement in the safety or effectiveness of the therapies. Johnson & Johnson does not endorse the practice of evergreening, which we view as distinct from incremental pharmaceutical innovation. 2

3 Patent Linkage Patent linkage refers to legislation that postpones marketing approval for any generic product covered by a patent until the expiration of all applicable data and/or patent exclusivities, or until a challenger establishes that the patent protection on the original product to be copied does not apply to the proposed generic version. Johnson & Johnson believes strong patent linkage acts as an effective safeguard measure. Linkage should be adopted by national authorities as an integral part of their patent systems. Data Exclusivity Data exclusivity is a type of IPright that is distinct from patent rights, one that is based on proprietary clinical test data. Data exclusivity is awarded in return for the originator/ owner of the clinical test data allowing later-filed generics the right to base their regulatory filings on that data. Johnson & Johnson believes that data exclusivity periods should be provided for all new drugs, including biologics, and the length of those periods should be commensurate with the generally high level of investment spent on developing these drugs. New drugs have the potential to fundamentally change the treatment of many diseases. National authorities should enact legislation authorizing abbreviated pathways for new drugs that appropriately balance the incentives to develop new medicines (which provide an opportunity for better health outcomes and overall cost savings) with the savings associated with entry of generic drugs and biosimilars into the marketplace. Enacting legislation that defines a base period of exclusivity plus a significant additional period of exclusivity for new indications or new formulations is one way to achieve this balance (in conjunction with other forms of protection such as patents and trade secrets). Compulsory Licensing A compulsory license is when a government allows someone else, usually a generic drug manufacturer, to produce a patented product or process without the consent of the patent owner. Johnson & Johnson supports the Doha Declaration and the flexibilities provided to national authorities under the Trade-Related Aspects of 3

4 Intellectual Property Rights (TRIPS) Agreement. At the same time, we believe that compulsory licenses to patent rights under the TRIPS Agreement should be used only in urgent circumstances, when all other alternatives have been exhausted. We oppose the regular use of compulsory licenses, for example, to support industrial policy objectives aimed at favoring domestic industries or simply as a cost-containment measure. Instead, Johnson & Johnson endeavors to offer other effective approaches that provide drug accessibility in developing and least developed markets, and provide local patients in those markets with high-quality product. Patent-Term Restoration, Adjustment and Extension Johnson & Johnson seeks to engage national patent authorities to explain the effectiveness of extending patent terms to compensate for patent protection lost because of delays in the regulatory approval process. We encourage the timely adoption of policies that fully compensate patent owners for the loss of such protection to ensure innovation in health care is adequately rewarded as an appropriate return for the investments made in research and development. Trademark Infringement Johnson & Johnson believes strong and effective trademark protection is in the interests of consumers, patients and governments as well as the innovative health care technologies industry. Remedies including administrative measures, civil actions or even criminal charges should be enacted and enforced effectively against trademark infringers who pose a serious risk to the health and safety of consumers worldwide. Voluntary Licensing Intellectual Property and Access and Affordability of Healthcare in Developing Countries Johnson & Johnson believes we have a responsibility to contribute to providing sustainable access to health care around the world, and that includes improving access to medicines in developing countries, particularly in least developed countries (LDCs). Our responsibility expresses itself in our tradition of philanthropy, the medical products we research and develop, the access and pricing programs we implement for those products, and the policy positions Johnson & Johnson supports in all parts of the world. 4

5 While IP may be one of many issues to be taken into account when considering access, importantly it plays no role in limiting access to the vast majority of essential medicines, which are not protected by IP. In certain circumstances, where patents describe an essential medicine, Johnson & Johnson has addressed the concerns of the LDCs by pledging not to enforce those patents, provided the generic versions of the drugs are quality products, medically acceptable and used in the defined territory. Under other circumstances, access-based voluntary licensing of IP covering Johnson & Johnson products and research tools has proven to be an effective method of striking a sustainable balance between public and commercial interests. Such licenses provide assurances to the licensee that the ancillary investments needed to make their licensed product available will enjoy a degree of protection against unlicensed users of the patented inventions. Johnson & Johnson believes public policy is best served when the licensing of IP is voluntary rather than compulsory, as inventors and developers of new medical technologies are better positioned to be fairly rewarded for their contributions, and incentivized to invest in the discovery, development and enhancement of needed new therapies. Last updated: May

TRIPS and Access to Medicines. WR Briefing

TRIPS and Access to Medicines. WR Briefing TRIPS and Access to Medicines WR Briefing Outline What is TRIPS How does it affect access to medicines What are the TRIPS flexibilities? What are extra-trips provisions? How do the extra-trips provisions

More information

Draft Plan of Action Chair's Text Status 3 May 2008

Draft Plan of Action Chair's Text Status 3 May 2008 Draft Plan of Action Chair's Text Status 3 May 2008 Explanation by the Chair of the Drafting Group on the Plan of Action of the 'Stakeholder' Column in the attached table Discussed Text - White background

More information

Standing Committee on the Law of Patents

Standing Committee on the Law of Patents E SCP/24/4 ORIGINAL: ENGLISH DATE: JUNE 29, 2016 Standing Committee on the Law of Patents Twenty-Fourth Session Geneva, June 27 to 30, 2016 PROPOSAL BY THE AFRICAN GROUP FOR A WIPO WORK PROGRAM ON PATENTS

More information

Standing Committee on the Law of Patents Twenty-Sixth Session

Standing Committee on the Law of Patents Twenty-Sixth Session Standing Committee on the Law of Patents Twenty-Sixth Session Marco M. ALEMAN Director, Patent Law Division, WIPO Geneva, July 3 to 6, 2017 SCP/26/5 CONSTRAINTS FACED BY DEVELOPING COUNTRIES AND LEAST

More information

B) Issues to be Prioritised within the Proposed Global Strategy and Plan of Action:

B) Issues to be Prioritised within the Proposed Global Strategy and Plan of Action: INTERGOVERNMENTAL WORKING GROUP ON PUBLIC HEALTH, INNOVATION AND INTELLECTUAL PROPERTY EGA Submission to Section 1 Draft Global Strategy and Plan of Action The European Generic Medicines Association is

More information

Regional Seminar for Certain African Countries on the Implementation and Use of Several Patent-Related Flexibilities

Regional Seminar for Certain African Countries on the Implementation and Use of Several Patent-Related Flexibilities REPUBLIC OF SOUTH AFRICA Regional Seminar for Certain African Countries on the Implementation and Use of Several Patent-Related Flexibilities Topic 7: Flexibilities Related to the Definition of Patentable

More information

TRIPs & PATENTS. In 1899, Mr. Charles H. Duell, Director of US Patent office said Everything that can be invented, has (already) been invented.

TRIPs & PATENTS. In 1899, Mr. Charles H. Duell, Director of US Patent office said Everything that can be invented, has (already) been invented. TRIPs & PATENTS Dr.Gopakumar G. Nair In 1899, Mr. Charles H. Duell, Director of US Patent office said Everything that can be invented, has (already) been invented. The events thereafter proved that inventions

More information

IPRs and Public Health: Lessons Learned Current Challenges The Way Forward

IPRs and Public Health: Lessons Learned Current Challenges The Way Forward Local Pharmaceutical Production in Africa International Conference Cape Town, 4-6 April 2011 IPRs and Public Health: Lessons Learned Current Challenges The Way Forward Roger Kampf WTO Secretariat 1 Acknowledging

More information

What is Intellectual Property?

What is Intellectual Property? What is Intellectual Property? Watch: Courtesy Swatch AG What is Intellectual Property? Table of Contents Page What is Intellectual Property? 2 What is a Patent? 5 What is a Trademark? 8 What is an Industrial

More information

TRIPS FLEXIBILITIES AND ACCESS TO MEDICINES

TRIPS FLEXIBILITIES AND ACCESS TO MEDICINES TRIPS FLEXIBILITIES AND ACCESS TO MEDICINES A European Approach Acknowledgements We are grateful to Ellen t Hoen for reviewing an earlier version of this brochure. Publisher Health Action International

More information

Carnegie Endowment for International Peace

Carnegie Endowment for International Peace Carnegie Endowment for International Peace How the U.S. and India could Collaborate to Strengthen Their Bilateral Relationship in the Pharmaceutical Sector Second Panel: Exploring the Gilead-India Licensing

More information

TRIPS, FTAs and BITs: Impact on Domestic IP- and Innovation Strategies in Developing Countries

TRIPS, FTAs and BITs: Impact on Domestic IP- and Innovation Strategies in Developing Countries Innovation, Creativity and IP Policy: An Indo-European Dialogue TRIPS, FTAs and BITs: Impact on Domestic IP- and Innovation Strategies in Developing Countries Henning Grosse Ruse NUJS & MPI Collaborative

More information

Intellectual Property Policy. DNDi POLICIES

Intellectual Property Policy. DNDi POLICIES Intellectual Property Policy DNDi POLICIES DNDi hereby adopts the following intellectual property (IP) policy: I. Preamble The mission of DNDi is to develop safe, effective and affordable new treatments

More information

Technology Commercialization Primer: Understanding the Basics. Leza Besemann

Technology Commercialization Primer: Understanding the Basics. Leza Besemann Technology Commercialization Primer: Understanding the Basics Leza Besemann 10.02.2015 Agenda Technology commercialization a. Intellectual property b. From lab to market Patents Commercialization strategy

More information

UNITAID The HIV/AIDS Medicines Patent Pool Initiative Overview

UNITAID The HIV/AIDS Medicines Patent Pool Initiative Overview UNITAID The HIV/AIDS Medicines Patent Pool Initiative Overview December 2009 UNITAID Mission UNITAID's Mission Scale up access to treatment for HIV/AIDS, malaria and TB Leverage price reductions of quality

More information

Descriptions of Workshops and Pharma Workshops for Helsinki 2013

Descriptions of Workshops and Pharma Workshops for Helsinki 2013 Descriptions of Workshops and Pharma Workshops for Helsinki 2013 1) IP licensing and insolvency The insolvency of technological giants such as Qimonda, BenQ or Kodak sends massive shockwaves into the world

More information

The TRIPS Tightrope public health, innovation, incentives and access

The TRIPS Tightrope public health, innovation, incentives and access International Federation of Pharmaceutical Manufacturers & Associations The TRIPS Tightrope public health, innovation, incentives and access Helsinki, 6 September 2013 1 IFPMA 2013 Definitions (I) Doha

More information

Dr. Biswajit Dhar Professor, Jawaharlal Nehru University, India and Member DA9 Advisory Board

Dr. Biswajit Dhar Professor, Jawaharlal Nehru University, India and Member DA9 Advisory Board Dr. Biswajit Dhar Professor, Jawaharlal Nehru University, India and Member DA9 Advisory Board Intellectual Property Rights in Preferential Trade Agreements Many Preferential Trade Agreements (PTAs) adopted

More information

An Essential Health and Biomedical R&D Treaty

An Essential Health and Biomedical R&D Treaty An Essential Health and Biomedical R&D Treaty Submission by Health Action International Global, Initiative for Health & Equity in Society, Knowledge Ecology International, Médecins Sans Frontières, Third

More information

Practical Strategies for Biotechnology and Medical Device Companies to Manage Intellectual Property Rights

Practical Strategies for Biotechnology and Medical Device Companies to Manage Intellectual Property Rights Practical Strategies for Biotechnology and Medical Device Companies to Manage Intellectual Property Rights Matt Jonsen Dorsey & Whitney LLP Angie Morrison Dorsey & Whitney LLP Intellectual Property Patents

More information

Pharmaceutical Patents in India - Seminar on Global l Best IPR Practices Indo American Chamber of Commerce

Pharmaceutical Patents in India - Seminar on Global l Best IPR Practices Indo American Chamber of Commerce Pharmaceutical Patents in India - Seminar on Global l Best IPR Practices Indo American Chamber of Commerce Tapan Ray March 29, 2008 - Mumbai INDIAN PHARMACEUTICAL INDUSTRY: 2006-2007 2007 U.S.$ 8 Bn. Domestic

More information

USTR NEWS UNITED STATES TRADE REPRESENTATIVE. Washington, D.C UNITED STATES MEXICO TRADE FACT SHEET

USTR NEWS UNITED STATES TRADE REPRESENTATIVE.   Washington, D.C UNITED STATES MEXICO TRADE FACT SHEET USTR NEWS UNITED STATES TRADE REPRESENTATIVE www.ustr.gov Washington, D.C. 20508 202-395-3230 FOR IMMEDIATE RELEASE August 27, 2018 Contact: USTR Public & Media Affairs media@ustr.eop.gov UNITED STATES

More information

Trans-Pacific Partnership Lost Important IP Provisions

Trans-Pacific Partnership Lost Important IP Provisions Portfolio Media. Inc. 111 West 19 th Street, 5th Floor New York, NY 10011 www.law360.com Phone: +1 646 783 7100 Fax: +1 646 783 7161 customerservice@law360.com Trans-Pacific Partnership Lost Important

More information

Chapter 15: Access to essential medicines, TRIPS and the patent system

Chapter 15: Access to essential medicines, TRIPS and the patent system Chapter 15: Access to essential medicines, TRIPS and the patent system SUMMARY POINTS All countries should develop a national medicines policy that includes a national list of essential medicines that

More information

ROLE OF INTELLECTUAL PROPERTY RIGHTS IN DEVELOPING COUNTRIES -ASHWINI SANDU.

ROLE OF INTELLECTUAL PROPERTY RIGHTS IN DEVELOPING COUNTRIES -ASHWINI SANDU. ROLE OF INTELLECTUAL PROPERTY RIGHTS IN DEVELOPING COUNTRIES -ASHWINI SANDU. Can you guess? How does one protect their brand? Most brands are distinct and being distinctive is the way potential users

More information

WIPO NATIONAL WORKSHOP FOR PATENT LAWYERS

WIPO NATIONAL WORKSHOP FOR PATENT LAWYERS ORIGINAL: English DATE: May 1997 GOVERNMENT OF THE FEDERAL DEMOCRATIC REPUBLIC OF ETHIOPIA WORLD INTELLECTUAL PROPERTY ORGANIZATION WIPO NATIONAL WORKSHOP FOR PATENT LAWYERS organized by the World Intellectual

More information

Regional Seminar on the Effective Implementation and Use of Several Patent-Related Flexibilities

Regional Seminar on the Effective Implementation and Use of Several Patent-Related Flexibilities DEPARTMENT OF INTELLECTUAL PROPERTY MINISTRY OF COMMERCE Regional Seminar on the Effective Implementation and Use of Several Patent-Related Flexibilities Topic 12: Which are Valid Grounds for a Compulsory

More information

Chapter 5 The Fundamentals of the Patent System

Chapter 5 The Fundamentals of the Patent System Chapter 5 The Fundamentals of the Patent System Chapter 5 The Fundamentals of the Patent System INTRODUCTION This chapter provides background information on the patent system that will facilitate understanding

More information

Topic 2: Patent-related Flexibilities in Multilateral Treaties and Their Importance for Developing Countries and LDCs

Topic 2: Patent-related Flexibilities in Multilateral Treaties and Their Importance for Developing Countries and LDCs Topic 2: Patent-related Flexibilities in Multilateral Treaties and Their Importance for Developing Countries and LDCs McLean Sibanda Chief Executive Officer - The Innovation Hub Second WIPO Inter-Regional

More information

19 Progressive Development of Protection Framework for Pharmaceutical Invention under the TRIPS Agreement Focusing on Patent Rights

19 Progressive Development of Protection Framework for Pharmaceutical Invention under the TRIPS Agreement Focusing on Patent Rights 19 Progressive Development of Protection Framework for Pharmaceutical Invention under the TRIPS Agreement Focusing on Patent Rights Research FellowAkiko Kato This study examines the international protection

More information

ACCOUNTING TREATMENT OF INTELLECTUAL PROPERTY IN THE PHARMACEUTICAL INDUSTRY

ACCOUNTING TREATMENT OF INTELLECTUAL PROPERTY IN THE PHARMACEUTICAL INDUSTRY Trakia Journal of Sciences, Vol. 9, No 4, pp 63-68, 2011 Copyright 2011 Trakia University Available online at: http://www.uni-sz.bg ISSN 1313-7069 (print) ISSN 1313-3551 (online) Original Contribution

More information

PATENT PROTECTION FOR PHARMACEUTICAL PRODUCTS IN CANADA CHRONOLOGY OF SIGNIFICANT EVENTS

PATENT PROTECTION FOR PHARMACEUTICAL PRODUCTS IN CANADA CHRONOLOGY OF SIGNIFICANT EVENTS PRB 99-46E PATENT PROTECTION FOR PHARMACEUTICAL PRODUCTS IN CANADA CHRONOLOGY OF SIGNIFICANT EVENTS Margaret Smith Law and Government Division 30 March 2000 Revised 31 May 2000 PARLIAMENTARY RESEARCH BRANCH

More information

Statement by the BIAC Committee on Technology and Industry on THE IMPACT OF INTELLECTUAL PROPERTY PROTECTION ON INNOVATION AND TECHNOLOGY DEVELOPMENT

Statement by the BIAC Committee on Technology and Industry on THE IMPACT OF INTELLECTUAL PROPERTY PROTECTION ON INNOVATION AND TECHNOLOGY DEVELOPMENT Business and Industry Advisory Committee to the OECD OECD Comité Consultatif Economique et Industriel Auprès de l l OCDE Statement by the BIAC Committee on Technology and Industry on THE IMPACT OF INTELLECTUAL

More information

Global strategy and plan of action on public health, innovation and intellectual property

Global strategy and plan of action on public health, innovation and intellectual property SIXTY-FIRST WORLD HEALTH ASSEMBLY WHA61.21 Agenda item 11.6 24 May 2008 Global strategy and plan of action on public health, innovation and intellectual property The Sixty-first World Health Assembly,

More information

UNCTAD Ad Hoc Expert Meeting on the Green Economy: Trade and Sustainable Development Implications November

UNCTAD Ad Hoc Expert Meeting on the Green Economy: Trade and Sustainable Development Implications November UNCTAD Ad Hoc Expert Meeting on the Green Economy: Trade and Sustainable Development Implications 8-10 November Panel 3: ENHANCING TECHNOLOGY ACCESS AND TRANSFER Good morning Ladies and Gentlemen. On behalf

More information

WHO workshop on IP and Vaccines. Geneva 19 th -20 th April Introduction to the IP issues Christopher Garrison Consultant to WHO

WHO workshop on IP and Vaccines. Geneva 19 th -20 th April Introduction to the IP issues Christopher Garrison Consultant to WHO WHO workshop on IP and Vaccines Geneva 19 th -20 th April 2004 Introduction to the IP issues Christopher Garrison Consultant to WHO Vaccine access, R&D and technology transfer issues are intimately linked

More information

Elements of a global strategy and plan of action

Elements of a global strategy and plan of action INTERGOVERNMENTAL WORKING GROUP A/PHI/IGWG/1/5 ON PUBLIC HEALTH, INNOVATION AND 8 December 2006 INTELLECTUAL PROPERTY Agenda item 2.3 Elements of a global strategy and plan of action Progress to date in

More information

Protecting Intellectual Property under TRIPS, FTAs and BITs: Conflicting Regimes or Mutual Coherence?

Protecting Intellectual Property under TRIPS, FTAs and BITs: Conflicting Regimes or Mutual Coherence? Protecting Intellectual Property under TRIPS, FTAs and BITs: Conflicting Regimes or Mutual Coherence? Henning Große Ruse International Investment Treaty Law and Arbitration Conference Sydney, 19-20 February

More information

International IP. Prof. Eric E. Johnson. General Principles

International IP. Prof. Eric E. Johnson. General Principles International IP Prof. Eric E. Johnson ericejohnson.com General Principles territoriality Dependence, independence, central attack Procedural harmonization Substantive agreements National treatment Minima

More information

December Eucomed HTA Position Paper UK support from ABHI

December Eucomed HTA Position Paper UK support from ABHI December 2008 Eucomed HTA Position Paper UK support from ABHI The Eucomed position paper on Health Technology Assessment presents the views of the Medical Devices Industry of the challenges of performing

More information

HTA Position Paper. The International Network of Agencies for Health Technology Assessment (INAHTA) defines HTA as:

HTA Position Paper. The International Network of Agencies for Health Technology Assessment (INAHTA) defines HTA as: HTA Position Paper The Global Medical Technology Alliance (GMTA) represents medical technology associations whose members supply over 85 percent of the medical devices and diagnostics purchased annually

More information

Indian Pharmaceutical Alliance. Responses to the issues raised in the Discussion Paper on the Utility Model

Indian Pharmaceutical Alliance. Responses to the issues raised in the Discussion Paper on the Utility Model Responses to the issues raised in the Discussion Paper on the Utility Model 30 June 2011 1 PREFACE The Department of Industrial Policy and Promotion, Ministry of Commerce has published a Discussion Paper

More information

Flexibilities in the Patent System

Flexibilities in the Patent System Flexibilities in the Patent System Dr. N.S. Gopalakrishnan Professor, HRD Chair on IPR School of Legal Studies, Cochin University of Science & Technology, Cochin, Kerala 1 Introduction The Context Flexibilities

More information

Access to Medicines, Patent Information and Freedom to Operate

Access to Medicines, Patent Information and Freedom to Operate TECHNICAL SYMPOSIUM DATE: JANUARY 20, 2011 Access to Medicines, Patent Information and Freedom to Operate World Health Organization (WHO) Geneva, February 18, 2011 (preceded by a Workshop on Patent Searches

More information

Using Academic Licensing Agreements to Promote Global Social Responsibility

Using Academic Licensing Agreements to Promote Global Social Responsibility Using Academic Licensing Agreements to Promote Global Social Responsibility Equitable Licensing of Medical Research Results Charité - Universitätsmedizin Berlin April 26, 2009 Dr. Ashley J. Stevens Executive

More information

Observations from Pharma

Observations from Pharma Observations from Pharma Indian Patent Enforcement in the Chemical Arts Gurmeet Kaur Sidhu, Senior Patent Litigation Counsel London, 26/9/11 a Novartis company The Indian Pharmaceutical sector: Overview

More information

TRAINING SEMINAR PHARMACEUTICALS AND INTELLECTUAL PROPERTY ACCESS TO MEDICINE: Exploitation of pharmaceutical patents: compulsory licences SESSION 4

TRAINING SEMINAR PHARMACEUTICALS AND INTELLECTUAL PROPERTY ACCESS TO MEDICINE: Exploitation of pharmaceutical patents: compulsory licences SESSION 4 TRAINING SEMINAR PHARMACEUTICALS AND INTELLECTUAL PROPERTY 1 12 14 March 2012 Pretoria, South Africa SESSION 4 ACCESS TO MEDICINE: COMMERCIALISATION, DISTRIBUTION, COMPETITION ----------------- Exploitation

More information

The TRIPS Agreement and Patentability Criteria

The TRIPS Agreement and Patentability Criteria WHO-WIPO-WTO Technical Workshop on Patentability Criteria Geneva, 27 October 2015 The TRIPS Agreement and Patentability Criteria Roger Kampf WTO Secretariat 1 Trilateral Cooperation: To Build Capacity,

More information

Effective Intellectual Property Management

Effective Intellectual Property Management Effective Intellectual Property Management Tom Smerdon Director, Licensing and New Business Development tom.smerdon@cu.edu NSF PV Workshop Golden, CO May 6, 2010 Knowledge Innovation Technology University

More information

TRIPS and Access to Medicines. The Story so far

TRIPS and Access to Medicines. The Story so far TRIPS and Access to Medicines The Story so far TRIPS and Access to Medicines : A brief history 1981: HIV first clinically observed 1982-83: Named AIDS 1984: Discovery that it is caused by a virus 1986:

More information

Discovery: From Concept to the Patient - The Business of Medical Discovery. Todd Sherer, Ph.D.

Discovery: From Concept to the Patient - The Business of Medical Discovery. Todd Sherer, Ph.D. Discovery: From Concept to the Patient - The Business of Medical Discovery Todd Sherer, Ph.D. Associate Vice President for Research and Director of OTT President Elect, Association of University Technology

More information

World Intellectual Property Organization. Topic C: Healthcare and Pharmacological Patents

World Intellectual Property Organization. Topic C: Healthcare and Pharmacological Patents World Intellectual Property Organization Topic C: Healthcare and Pharmacological Patents The policy balance between encouraging innovation and ensuring the widespread enjoyment of the social benefit of

More information

1. Recognizing that some of the barriers that impede the diffusion of green technologies include:

1. Recognizing that some of the barriers that impede the diffusion of green technologies include: DATE: OCTOBER 21, 2011 WIPO GREEN THE SUSTAINABLE TECHNOLOGY MARKETPLACE CONCEPT DOCUMENT EXECUTIVE SUMMARY 1. Recognizing that some of the barriers that impede the diffusion of green technologies include:

More information

How the Trans-Pacific Partnership Agreement Threatens Access to Medicines

How the Trans-Pacific Partnership Agreement Threatens Access to Medicines How the Trans-Pacific Partnership Agreement Threatens Access to Medicines The eighth round of closed-door negotiations for the Trans-Pacific Partnership (TPP) agreement will be held in Chicago from September

More information

Patenting trends in Indian pharmaceutical industry

Patenting trends in Indian pharmaceutical industry Annals of Library and Information Studies Vol. 64, December 2017, pp. 260-267 Patenting trends in Indian pharmaceutical industry Pratibha Gokhale a and Sudha Kannan b a Former Head, Department of Library

More information

China: Managing the IP Lifecycle 2018/2019

China: Managing the IP Lifecycle 2018/2019 China: Managing the IP Lifecycle 2018/2019 Patenting strategies for R&D companies Vivien Chan & Co Anna Mae Koo and Flora Ho Patenting strategies for R&D companies By Anna Mae Koo and Flora Ho, Vivien

More information

Regional Seminar for Certain African Countries on the Implementation and Use of Several Patent-Related Flexibilities

Regional Seminar for Certain African Countries on the Implementation and Use of Several Patent-Related Flexibilities REPUBLIC OF SOUTH AFRICA Regional Seminar for Certain African Countries on the Implementation and Use of Several Patent-Related Flexibilities Topic 15: The Impact of National Exhaustion of Rights on the

More information

IP Strategies to Enhance Competitiveness: India s Experience

IP Strategies to Enhance Competitiveness: India s Experience IP Strategies to Enhance Competitiveness: India s Experience N. N. Prasad Wednesday July 15, 2009 Innovation in Brazil, India and South Africa: A New Drive for Economic Growth and Development Strategy

More information

WTO NEGOTIATIONS ON TRIPS AND PUBLIC HEALTH: AN OVERVIEW. Jayashree Watal WTO Secretariat

WTO NEGOTIATIONS ON TRIPS AND PUBLIC HEALTH: AN OVERVIEW. Jayashree Watal WTO Secretariat WTO NEGOTIATIONS ON TRIPS AND PUBLIC HEALTH: AN OVERVIEW Jayashree Watal WTO Secretariat Outline Background to discussions in the TRIPS Council, including WHO-WTO Workshop on Differential Pricing and Financing

More information

Enforcement of Intellectual Property Rights Frequently Asked Questions

Enforcement of Intellectual Property Rights Frequently Asked Questions EUROPEAN COMMISSION MEMO Brussels/Strasbourg, 1 July 2014 Enforcement of Intellectual Property Rights Frequently Asked Questions See also IP/14/760 I. EU Action Plan on enforcement of Intellectual Property

More information

OMCL Network of the Council of Europe GENERAL DOCUMENT

OMCL Network of the Council of Europe GENERAL DOCUMENT OMCL Network of the Council of Europe GENERAL DOCUMENT PA/PH/OMCL (09) 87 4R OMCL Network support for the implementation of the CoE MEDICRIME Convention Full document title and reference How the OMCL Network

More information

Draft global strategy on public health, innovation and intellectual property

Draft global strategy on public health, innovation and intellectual property IGWG: Outcome document at 14.00 hours, Saturday 3 May 2008 Draft global strategy on public health, innovation and intellectual property The context 1. In resolution WHA59.24 the Health Assembly recognized

More information

5 th Annual Pharma IPR Conference 2016

5 th Annual Pharma IPR Conference 2016 5 th Annual Pharma IPR Conference 2016 9 11 March 2016, Mumbai DAY 1 : 9 th March 2016 Country: US 09:40 American Invents Act Updates on Americas Invents Act and current scenario of US Patent laws Implications

More information

Topic 2: The Critical Role of IP Policies in Modern Economies

Topic 2: The Critical Role of IP Policies in Modern Economies Topic 2: The Critical Role of IP Policies in Modern Economies McLean Sibanda Partner: Sibanda & Zantwijk Attorneys, South Africa THE ROLE OF INTELLECTUAL PROPERTY OFFICES (IPOs) IN PROMOTING INNOVATION,

More information

University Tech Transfer

University Tech Transfer Intellectual Property and University Tech Transfer Robert Hardy Director, Contracts & IP Management Council on Governmental Relations May 9, 2008 A Word About COGR Council on Governmental Relations (COGR)

More information

INTELLECTUAL PROPERTY OVERVIEW. Patrícia Lima

INTELLECTUAL PROPERTY OVERVIEW. Patrícia Lima INTELLECTUAL PROPERTY OVERVIEW Patrícia Lima October 14 th, 2015 Intellectual Property INDUSTRIAL PROPERTY (INPI) COPYRIGHT (IGAC) It protects technical and aesthetical creations, and trade distinctive

More information

The role of IP and other enabling factors for innovation and uptake of climate relevant technologies WIPO Green technology database and services

The role of IP and other enabling factors for innovation and uptake of climate relevant technologies WIPO Green technology database and services The role of IP and other enabling factors for innovation and uptake of climate relevant technologies WIPO Green technology database and services Anja von der Ropp Program Officer, Global Challenges Division,

More information

Public Hearings Concerning the Evolving Intellectual Property Marketplace

Public Hearings Concerning the Evolving Intellectual Property Marketplace [Billing Code: 6750-01-S] FEDERAL TRADE COMMISSION Public Hearings Concerning the Evolving Intellectual Property Marketplace AGENCY: Federal Trade Commission. ACTION: Notice of Public Hearings SUMMARY:

More information

Establishing a Development Agenda for the World Intellectual Property Organization

Establishing a Development Agenda for the World Intellectual Property Organization 1 Establishing a Development Agenda for the World Intellectual Property Organization to be submitted by Brazil and Argentina to the 40 th Series of Meetings of the Assemblies of the Member States of WIPO

More information

THE IMPACT OF INTELLECTUAL PROPERTY PROTECTION ON INNOVATION AND TECHNOLOGY DEVELOPMENT

THE IMPACT OF INTELLECTUAL PROPERTY PROTECTION ON INNOVATION AND TECHNOLOGY DEVELOPMENT Business and Industry Advisory Committee to the OECD Comité Consultatif Economique et Industriel Auprès de l OCDE OCDE THE IMPACT OF INTELLECTUAL PROPERTY PROTECTION ON INNOVATION AND TECHNOLOGY DEVELOPMENT

More information

MedTech Europe position on future EU cooperation on Health Technology Assessment (21 March 2017)

MedTech Europe position on future EU cooperation on Health Technology Assessment (21 March 2017) MedTech Europe position on future EU cooperation on Health Technology Assessment (21 March 2017) Table of Contents Executive Summary...3 The need for healthcare reform...4 The medical technology industry

More information

TECHNOLOGY TRANSFER AT THE UNIVERSITY OF TENNESSEE: INVENTIONS AND COMMERCIALIZATION

TECHNOLOGY TRANSFER AT THE UNIVERSITY OF TENNESSEE: INVENTIONS AND COMMERCIALIZATION utrf@tennessee.com TECHNOLOGY TRANSFER AT THE UNIVERSITY OF TENNESSEE: INVENTIONS AND COMMERCIALIZATION Hot Topics in Research, May 23, 2017 Richard Magid, PhD UTRF Vice President WHAT IS TECHNOLOGY TRANSFER?

More information

Americas Trade and Sustainable Development Forum (ATSDF) November 2003, Miami. Trade, Knowledge and Intellectual Property Rights Thematic Tent

Americas Trade and Sustainable Development Forum (ATSDF) November 2003, Miami. Trade, Knowledge and Intellectual Property Rights Thematic Tent Americas Trade and Sustainable Development Forum (ATSDF) 17-18 November 2003, Miami Trade, Knowledge and Intellectual Property Rights Thematic Tent CONCLUSIONS On behalf of the Trade, Knowledge and Intellectual

More information

Translational scientist competency profile

Translational scientist competency profile C-COMEND Competency profile for Translational Scientists C-COMEND is a two-year European training project supported by the Erasmus plus programme, which started on November 1st 2015. The overall objective

More information

Fixing Canada s Access to Medicines Regime (CAMR): 20 Questions & Answers

Fixing Canada s Access to Medicines Regime (CAMR): 20 Questions & Answers Fixing Canada s Access to Medicines Regime (CAMR): 20 Questions & Answers In this document: Questions 1 to 4 give a quick overview of CAMR and why it needs to be fixed. Questions 5 to 11 provide more in-depth,

More information

Lundbeck s view on the EU IP systems

Lundbeck s view on the EU IP systems Lundbeck s view on the EU IP systems Forårsmøde IPR in the EU May 26 2011 H. Lundbeck A/S 1 Agenda The Innovative Pharmaceutical Industry and why IP is so important for Lundbeck Lundbeck s wish list for

More information

HIV and co-infection medicines

HIV and co-infection medicines IP and regulatory barriers in LMICs HIV and co-infection medicines APACC, 2018 Hongkong, June 2018 Monopolies linked to Prices Monopoly No monopoly One supplier Multiple suppliers No competition Competition

More information

INSTITUTE OF MEDICINE COMMITTEE ON THE U.S. COMMITMENT TO GLOBAL HEALTH

INSTITUTE OF MEDICINE COMMITTEE ON THE U.S. COMMITMENT TO GLOBAL HEALTH INSTITUTE OF MEDICINE COMMITTEE ON THE U.S. COMMITMENT TO GLOBAL HEALTH Sharing Information, Knowledge and Materials Dr. Ashley J. Stevens Executive Director, Technology Transfer Senior Research Associate

More information

University joins Industry: IP Department. Georgina Marjanet Ferrer International, SA

University joins Industry: IP Department. Georgina Marjanet Ferrer International, SA University joins Industry: IP Department Georgina Marjanet Ferrer International, SA Topics Ø What is IP? Ø Importance of IP in the pharmaceutical industry Ø IP Department: tasks and responsibilities Ø

More information

Alternatives to the patent system used to support R&D Efforts. James Love WIPO Expert Forum on International Technology Transfer February 17, 2015

Alternatives to the patent system used to support R&D Efforts. James Love WIPO Expert Forum on International Technology Transfer February 17, 2015 Alternatives to the patent system used to support R&D Efforts James Love WIPO Expert Forum on International Technology Transfer February 17, 2015 Some conclusions {p1} The grant of exclusive rights to

More information

1. TRIPS, intellectual property rights and access to medicines a,b

1. TRIPS, intellectual property rights and access to medicines a,b UHC Technical brief 1. TRIPS, intellectual property rights and access to medicines a,b What is the TRIPS Agreement? The Agreement on Trade-Related Aspects of Intellectual Property Rights (or the TRIPS

More information

THE AMERICAN INTELLECTUAL PROPERTY LAW ASSOCIATION RECOMMENDATIONS REGARDING QUALIFICATIONS FOR

THE AMERICAN INTELLECTUAL PROPERTY LAW ASSOCIATION RECOMMENDATIONS REGARDING QUALIFICATIONS FOR THE AMERICAN INTELLECTUAL PROPERTY LAW ASSOCIATION RECOMMENDATIONS REGARDING QUALIFICATIONS FOR THE NEXT DIRECTOR AND DEPUTY DIRECTOR OF THE U.S. PATENT AND TRADEMARK OFFICE Revised and approved, AIPLA

More information

TRIPS Agreement and its Impact on Health

TRIPS Agreement and its Impact on Health SEA-HSD-277 Distribution: General TRIPS Agreement and its Impact on Health Report on a National Workshop Yangon, Myanmar, 13-15 October 2003 WHO Project: MMR EDM 001 World Health Organization Regional

More information

Loyola University Maryland Provisional Policies and Procedures for Intellectual Property, Copyrights, and Patents

Loyola University Maryland Provisional Policies and Procedures for Intellectual Property, Copyrights, and Patents Loyola University Maryland Provisional Policies and Procedures for Intellectual Property, Copyrights, and Patents Approved by Loyola Conference on May 2, 2006 Introduction In the course of fulfilling the

More information

BIPF Munich. South Africa Enforcement of Pharmaceutical Patents and the New Draft IP Policy

BIPF Munich. South Africa Enforcement of Pharmaceutical Patents and the New Draft IP Policy BIPF 2014 - Munich South Africa Enforcement of Pharmaceutical Patents and the New Draft IP Policy Russell Bagnall Danie Dohmen 1 OVERVIEW Enforcement of Pharmaceutical Patents The Role Players Compulsory

More information

Implementing Global Strategy and Plan of Action on Public Health, Innovation and Intellectual Property in the Eastern Mediterranean Region

Implementing Global Strategy and Plan of Action on Public Health, Innovation and Intellectual Property in the Eastern Mediterranean Region Implementing Global Strategy and Plan of Action on Public Health, Innovation and Intellectual Property in the Eastern Mediterranean Region 1 Table of Contents LIST OF ACRONYMS AND ABBREVIATIONS -----------------------------------------------------------------------------------

More information

ECU Research Commercialisation

ECU Research Commercialisation The Framework This framework describes the principles, elements and organisational characteristics that define the commercialisation function and its place and priority within ECU. Firstly, care has been

More information

Nitya Nanda. The Energy and Resources Institute (TERI)

Nitya Nanda. The Energy and Resources Institute (TERI) Nitya Nanda The Energy and Resources Institute (TERI) Arguments for and against patent protection The climate change context Perspectives on IPR and technology transfer Patent regimes in developing countries

More information

PROTECTION OF INTELLECTUAL PROPERTY

PROTECTION OF INTELLECTUAL PROPERTY Chapter 12 PROTECTION OF INTELLECTUAL PROPERTY OVERVIEW OF RULES In today s economic environment, intangible assets are becoming increasingly important. These assets, which are the result of human intellectual

More information

WIPO-IFIA INTERNATIONAL SYMPOSIUM ON THE COMMERCIALIZATION OF INVENTIONS IN THE GLOBAL MARKET

WIPO-IFIA INTERNATIONAL SYMPOSIUM ON THE COMMERCIALIZATION OF INVENTIONS IN THE GLOBAL MARKET ORIGINAL: English DATE: December 2002 E INTERNATIONAL FEDERATION OF INVENTORS ASSOCIATIONS WORLD INTELLECTUAL PROPERTY ORGANIZATION WIPO-IFIA INTERNATIONAL SYMPOSIUM ON THE COMMERCIALIZATION OF INVENTIONS

More information

April 21, By to:

April 21, By  to: April 21, 2017 Mr. Qiu Yang Office of the Anti-Monopoly Commission Of the State Council of the People s Republic of China No. 2 East Chang an Avenue, Beijing P.R. China 100731 By Email to: qiuyang@mofcom.gov.cn

More information

eskbook Emerging Life Sciences Companies second edition Chapter 8 Checklist for Planning and Conducting an Effective FTO Search

eskbook Emerging Life Sciences Companies second edition Chapter 8 Checklist for Planning and Conducting an Effective FTO Search eskbook Emerging Life Sciences Companies second edition Chapter 8 Checklist for Planning and Conducting an Effective FTO Search Chapter 8 CHECKLIST FOR PLANNING AND CONDUCTING AN EFFECTIVE FTO SEARCH The

More information

Patients Must Have Immediate Access to Affordable Generic Medicines at Day One After Patent Expiry

Patients Must Have Immediate Access to Affordable Generic Medicines at Day One After Patent Expiry Patients Must Have Immediate Access to Affordable Generic Medicines at Day One After Patent Expiry Generic Medicines: Key to Healthcare Sustainability and Patient Care EGA represents over 700 companies

More information

SUPPORT NOTES UNIT 3: INSIDE THE LINES

SUPPORT NOTES UNIT 3: INSIDE THE LINES SUPPORT NOTES UNIT 3: INSIDE THE LINES PRODUCT DESIGN Including video interviews with experts, this activity encourages students to reflect on the difference between trademarks, patents and registered

More information

the Companies and Intellectual Property Commission of South Africa (CIPC)

the Companies and Intellectual Property Commission of South Africa (CIPC) organized by the Companies and Intellectual Property Commission of South Africa (CIPC) the World Intellectual Property Organization (WIPO) the International Criminal Police Organization (INTERPOL) the

More information

Comments of the AMERICAN INTELLECTUAL PROPERTY LAW ASSOCIATION. Regarding

Comments of the AMERICAN INTELLECTUAL PROPERTY LAW ASSOCIATION. Regarding Comments of the AMERICAN INTELLECTUAL PROPERTY LAW ASSOCIATION Regarding THE ISSUES PAPER OF THE AUSTRALIAN ADVISORY COUNCIL ON INTELLECTUAL PROPERTY CONCERNING THE PATENTING OF BUSINESS SYSTEMS ISSUED

More information

Ethiopia s Accession to World Trade Organization (WTO): The Need to Reform Ethiopian Patent Law to Facilitate Access to Medicine PART I

Ethiopia s Accession to World Trade Organization (WTO): The Need to Reform Ethiopian Patent Law to Facilitate Access to Medicine PART I w w w. a b y s s i n i a l a w. c o m P a g e 1 Ethiopia s Accession to World Trade Organization (WTO): The Need to Reform Ethiopian Patent Law to Facilitate Access to Medicine Abstract As a country dealing

More information

Presented at GIZ/SAWTEE Training on IPR 1-2 March 2012, Laltipur. Ratnakar Adhikari South Asia Watch on Trade, Economics and Environment

Presented at GIZ/SAWTEE Training on IPR 1-2 March 2012, Laltipur. Ratnakar Adhikari South Asia Watch on Trade, Economics and Environment Presented at GIZ/SAWTEE Training on IPR 1-2 March 2012, Laltipur Ratnakar Adhikari South Asia Watch on Trade, Economics and Environment Genesis and background Patent provisions in the TRIPS Agreement Nepalese

More information

Compulsory Licensing:

Compulsory Licensing: HESO 449B Compulsory Licensing: An effective tool to increasing access to essential medicines? Julia Wu Submitted on April 7 th, 2010 Realizing that patent protection on pharmaceutical products can restrict

More information

Submission to the Productivity Commission inquiry into Intellectual Property Arrangements

Submission to the Productivity Commission inquiry into Intellectual Property Arrangements Submission to the Productivity Commission inquiry into Intellectual Property Arrangements DECEMBER 2015 Business Council of Australia December 2015 1 Contents About this submission 2 Key recommendations

More information